SOCS, inflammation, and cancer
Kyoko Inagaki-Ohara1, Taisuke Kondo, Minako Ito
1Department of Gastroenterology; Research Center for Hepatitis and Immunology; Research Institute; National Center for Global Health and Medicine (NCGM); Ichikawa, Japan.
Abstract:
Signal transduction pathways elicited by cytokines and hormones have been shown to regulate distinct stages of development. Suppressor of cytokine signaling (SOCS) proteins are negative feedback regulators of cytokine signaling mediated by the JAK-STAT signaling pathway. In particular, SOCS1 and SOCS3 are potent inhibitors of JAKs and can play pivotal roles in inflammation, as well as in the development and progression of cancers. Abnormal expression of SOCS1 and SOCS3 in cancer cells has been reported in human carcinoma associated with dysregulation of signals from cytokine receptors, Toll-like receptors (TLRs), and hormone receptors, resulting in malignancies. In this review, we focus on the role of SOCS1 and SOCS3 in cancer development. In addition, the potential of SOCS as a therapeutic target and diagnostic aid will be discussed.
Insights
Suppressor of cytokine signaling (SOCS) proteins, particularly SOCS1 and SOCS3, are key regulators of the JAK-STAT pathway. Their abnormal expression in cancer cells highlights their role in malignancies and potential as therapeutic targets.
Area of Science:
- Molecular Biology
- Cell Signaling
- Oncology
Background:
- Cytokines and hormones regulate development via signal transduction.
- Suppressor of cytokine signaling (SOCS) proteins are negative feedback regulators of JAK-STAT signaling.
- SOCS1 and SOCS3 inhibit JAKs, influencing inflammation and cancer progression.
Purpose of the Study:
- To review the role of SOCS1 and SOCS3 in cancer development.
- To discuss the potential of SOCS proteins as therapeutic targets and diagnostic aids in oncology.
Main Methods:
- Literature review focusing on SOCS1 and SOCS3 function in cancer.
- Analysis of abnormal SOCS1 and SOCS3 expression in human carcinomas.
- Examination of dysregulated signaling pathways involving cytokine, TLR, and hormone receptors.
Main Results:
- Abnormal SOCS1 and SOCS3 expression is linked to malignancies.
- SOCS1 and SOCS3 play pivotal roles in inflammation and cancer progression.
- Dysregulation of cytokine, TLR, and hormone receptor signaling is associated with abnormal SOCS expression in cancer cells.
Conclusions:
- SOCS1 and SOCS3 are critical in cancer development and progression.
- Targeting SOCS proteins offers potential for cancer therapy and diagnostics.
Related Concept Videos
Inflammation
Inflammation: Introduction
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammatory Response I: Vascular and Cellular
Chronic Inflammation: Introduction
Psychoneuroimmunology: Diabetes and Cancer

